APP and Alzheimer disease: Furthermore, the 5-HT2AR inverse agonist Pimavanserin has been demonstrated to reduce Aβ production and deposition in the interstitial fluid (ISF) of AD mice by increasing α-secretase-dependent cleavage of amyloid precursor protein (APP), thereby improving cognitive function and memory performance.